罗格列酮治疗2型糖尿病的安全性。
The safety of rosiglitazone in the treatment of type 2 diabetes.
作者信息
Singh Sonal, Loke Yoon K
机构信息
Wake Forest University School of Medicine, Department of Medicine, Winston-Salem, NC 27103, USA.
出版信息
Expert Opin Drug Saf. 2008 Sep;7(5):579-85. doi: 10.1517/14740338.7.5.579.
BACKGROUND
Cardiovascular disease is the leading cause of mortality among adults with Type 2 diabetes. The thiazolidinediones including rosiglitazone are approved for the treatment of Type 2 diabetes on the basis of their ability to lower blood sugar and surrogate markers of cardiovascular disease.
OBJECTIVES
To ascertain the cardiovascular, skeletal and hematologic safety profile of rosiglitazone.
METHODS
Synthesis of evidence from recent trials, systematic reviews, meta-analysis, regulatory documents and clinical trials registries of manufacturers.
CONCLUSION
Rosiglitazone increases the risk of heart failure, myocardial infarction and fractures (in women) with Type 2 diabetes.
背景
心血管疾病是2型糖尿病成年患者死亡的主要原因。包括罗格列酮在内的噻唑烷二酮类药物因其降低血糖和心血管疾病替代指标的能力而被批准用于治疗2型糖尿病。
目的
确定罗格列酮的心血管、骨骼和血液学安全性。
方法
综合近期试验、系统评价、荟萃分析、监管文件以及制造商的临床试验注册信息中的证据。
结论
罗格列酮会增加2型糖尿病患者发生心力衰竭、心肌梗死和骨折（女性）的风险。
Zotero 插件